LONDON (ShareCast) - (Sharecast News) - Medical device company Creo Medical Group announced on Friday that the Queen Elizabeth and the Queen Mother Hospital in Margate (QEQM Hospital), part of the East Kent University Hospitals Foundation Trust, had entered into the second day of a two-day endoscopy training course for more than 40 UK clinicians, which would include live demonstrations and training on Creo's 'Speedboat' device and 'CROMA' advanced energy platform.
The AIM-traded firm said the endoscopy training course was being led by Dr Zacharias Tsiamoulos, consultant in gastroenterology and specialist in GI endoscopy at the East Kent Trust, and Professor Yutaka Saito, director of the endoscopy division at the National Cancer Center Hospital in Tokyo.

It said the course was being sponsored by Creo and Diagmed Healthcare, Creo's UK distribution partner, among others.

Dr Tsiamoulos was a "key opinion leader" in the field of gastrointestinal (GI) therapeutic endoscopy, and a leading user of Creo's 'Speedboat' device for colorectal endoscopic submucosal dissection - an advanced surgical procedure using endoscopy to remove gastrointestinal precancerous lesions that had not entered the muscle layer.

Creo said Dr Tsiamoulos trained in the procedure in Japan under key opinion leader Professor Saito - one of the global pioneers in therapeutic endoscopy, according to the company.

The course supported Creo's education-led strategy, and reflected Diagmed's commitment to advance the rollout of Creo's clinical education programme in the UK, ensuring quality control and best patient outcomes through the education of key clinicians in the use of Speedboat and the CROMA platform.

It said the two-day event would allow delegates to observe a number of live procedures undertaken by Dr Tsiamoulos using Creo's Speedboat, which could deliver bipolar radiofrequency for precise localised cutting, and microwave energy for controlled coagulation.

Dr Tsiamoulos would also provide direct training to delegates on the techniques required to successfully undertake endoscopic submucosal dissection procedures using the Speedboat device as an outpatient procedure, helping to reduce the risks associated with alternative open and laparoscopic procedures, reducing the length of stay in hospital for the patient, and reducing the cost of treatment and transferring therapy from the operating theatre to the endoscopy room.

"Our strategy has always been focused on ensuring that key clinicians are educated in the use of Speedboat and the CROMA platform to safeguard quality control and best patient outcomes," said Creo chief executive officer Craig Gulliford.

"This training course at the QEQM hospital, and our wider clinical education programme, aims to ensure that the first adopters of our technology, having been carefully mentored by our own doctors and endoscopy nurses, can deliver consistently high standards in this emerging field of surgical endoscopy."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE